Interferon-based therapy for chronic hepatitis C: Current and future perspectives

Hepatitis Monthly

Volumn 10, Issue 3, 2010, Pages 231-232

  de Re, Valli ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; TELAPREVIR;

B LYMPHOCYTE; CELL ADHESION; CHRONIC DISEASE; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NEUTROPENIA; PATIENT COMPLIANCE; TREND STUDY;

EID: 77954875728     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Alavian SM, Behnava B, Tabatabaei SV. The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis. Hepat Mon. 2010;10(2):121-31.
2. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther. 2000;6(3):149-54.
3. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995;42(6):907-12.
4. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46(3):631-9.
5. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50(6):1709-18.
6. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49(2):163-9.
7. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-38.
8. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
9. Akuta N, Suzuki F, Hirakawa M, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology. 2009;52(6):301-9.
10. Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44(9):952-63.
11. Stamataki Z, Shannon-Lowe C, Shaw J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood. 2009;113(3):585-93.
12. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-{alpha}, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010. [in press].